Prena, Inc. focused on developing and commercializing in-licensed technologies that will meet significant unmet medical needs in Women’s Health. KynderMed’s initial portfolio is comprised of two potential products that are based upon technology developed within the Florida State University College of Medicine. The current intellectual property estate is comprised of two issued patents, four that are pending and one provisional. The Company’s lead product is a medical device to prevent at-risk women from entering pre-term labor. One in four pregnancies is at-risk of preterm delivery. Preterm births result in the deaths of one million babies per year globally, and leave another two million with serious lifelong disabilities such as cerebral palsay, profound retardation, blindness and deafness. . There is currently no therapy that can safely and effectively prevent the onset of preterm labor. The burden on the US healthcare system alone for preterm neonatal care exceeds $25 billion. The key science has been tested in pregnant women in two Proof of Concept trials: one at Tallahassee Memorial Hospital and the other at Brigham and Women’s Hospital (Harvard). KynderMed anticipates that the pivotal clinical trial result in approvals in the US and Europe in early - mid 2017.